News

June 1, 2020

In an effort to focus the development of topical zafirlukast, the company has decided to concentrate resources on the application fro allergic eye disorders.  The decision was based on the preclinical experiments in animal models of conjunctivitis as well as the compel...

April 30, 2014

WILMINGTON, Del.—Accolade Pharmaceuticals is proud to announce today the appointment of Dr. James P. Kemp, as Chief Medical Officer. He will be the newest member of the Accolade management team, which includes six members with extensive backgrounds in the biopharmaceut...

October 28, 2013

WILMINGTON, Del.— Accolade Pharmaceuticals LLC announced today the signing of a global licensing agreement with Australian life sciences company, Invion Limited, for the development and commercialization of inhaled formulations for the asthma treatment drug, zafirlukas...

December 20, 2012

WILMINGTON, Del.—Six former drug industry executives have announced today the formation of Accolade Pharmaceuticals LLC, a specialty biopharmaceutical company focused on developing a range of products for the treatment of allergic disorders. The Company will focus its...

Please reload

©  2020 Accolade Pharma, LLC

42 Hill Road

Wilmington, DE 19806

302-427-2985